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Abstract
Purpose To examine the relationship between serum total
oxidant (TOS) and antioxidant (TAS) levels and clinical preg-
nancy in assisted reproductive technology (ART) cycles.
Methods Prior to and after oocyte pick-up (OPU) and em-
bryo transfer (ET), blood samples were collected from
gynecologically normal females (n=70) who were enrolled
for ART solely due to male factor infertility. TAS, TOS
levels and oxidative stress indexes (OSI: TOS/TAS) in four
phases of treatment cycle (pre and post OPU and ET)
between clinically pregnant and non-pregnant patients were
compared. Critical cut-off values of significantly different
TAS, TOS levels and OSIes for clinical pregnancy were
established.
Results The TAS levels in patients with clinical pregnancywere
significantly higher in all of the four phases of the cycle. Post-
OPU and pre-ET TOS levels were significantly higher in clin-
ically pregnant patients. According to OSIes; only the pre-OPU
OSI was significantly lower in clinically pregnant patients com-
pared with non-pregnant ones. Moreover, the highest area under
the ROC curve (AUC) from the seven different significant
measurements [1) pre-OPU OSI, 2) pre-OPU TAS, 3) post-
OPU TAS, 4) pre-ET TAS, 5) post-ET TAS, 6) post-OPU
TOS, 7) pre-ET TOS] was related to pre-OPU OSI.
Conclusions In ART cycles, women with a higher total
antioxidant status prior to and after OPU and prior to and
after ET have an increased probability of clinical pregnancy.
Additionally; OSI before OPU was one of the most impor-
tant determinants for clinical pregnancy, so the oxidant and
antioxidant balance is as important as the antioxidant con-
centration alone.
Keywords Assisted reproductive technology . Fertility .
Oxidative stress . Pregnancy
Introduction
Considering recent studies, it is believed that the oxidative
stress balance plays a significant role in the normal func-
tioning of the female reproductive system as well as many
other systems. The development of imbalance between ox-
idants and antioxidants in the female reproductive system
results in oxidative stress (OS) [1]. It was shown that
Capsule In ART-ICSI cycles, women with lower oxidative stress index
(OSI: TOS/TAS) measurements prior to oocyte collection, may have
increased probability of clinical pregnancy.
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reactive oxygen species (ROS), which are markers of oxi-
dative stress, in follicular fluid, are important factors in the
development and quality of embryos [7]. In another group of
studies, the ROS level in embryo culture medium was
reported to negatively affect embryo cleavage and could even
help to predict clinical pregnancies [5, 6]. Considering these
findings, the ROS level observed as an embryonic metabolic
marker in embryo culture medium can be used as one of the
criteria for embryo selection, and more clinical pregnancies
can be attained by single ET, which can be performed based
on this approach [12].
In contrast, oxidative stress markers in peritoneal fluid were
higher in unexplained infertile couples, which constitutes one
of the major patient groups among infertile individuals [2].
However, in patients with endometriosis, in which the worst
results are expected in ART treatment, the antioxidant levels
were found to be lower [17]. Today, there is no debate that
especially in infertile couples, oxidative stress has an impact on
many characteristics, including follicular fluid, embryo culture
medium, the endometrial implantation phase and the continu-
ity of the corpus luteum [2]. However, most of the studies on
the effect of oxidative stress on female infertility were animal
or in vitro studies, and their results were contradictory [3].
Our aim in this study was to examine the relationship
between serum total oxidant and antioxidant levels and clin-
ical pregnancy and evaluate this relationship in terms of
predicting clinical pregnancy in 70 couples who were admit-
ted to ART treatment solely because of male factor infertility;
in these couples, the women were completely normal from a
fertility perspective. To our knowledge, no study in the liter-
ature has examined the correlation between blood total oxi-
dant and antioxidant levels and clinical pregnancy in women
with normal characteristics who were admitted to ART treat-
ment solely due to male factor infertility.
Methods
This prospective cohort study was conducted between
September 2011 and July 2012 at Eskisehir Osmangazi
University, Medical Faculty-Center for Reproductive
Health, and approved by the Ethical Review Board of the
hospital. A total of 70 patients attending the IVF unit of the
center for ICSI cycles were recruited according to the fol-
lowing criteria: i) absence of any apparent abnormality of
the reproductive system, as revealed by their medical histo-
ry, clinical examinations and common hormonal tests; ii)
absence of any metabolic or endocrine system-associated
diseases, such as hyperprolactinemia, thyroid dysfunction,
or polycystic ovary syndrome as defined by the Rotterdam
criteria; iii) absence of any surgical history regarding the
reproductive system; iv) normal ovulatory cycle, with cycle
lengths of between 25 and 35 days; v) age of women
between 27 and 36 years; vi) expected normal responders, as
day 3 basal ultrasonography and a hormone profile revealed the
following among all the women: FSH <10 mIU/ml, estradiol
<40 pg/ml and antral follicle count (AFC) >6; vii) absence of
any smoking history in women; and viii) indication for assisted
reproductive technology (ART) treatment as exclusively ad-
vanced male factor infertility (severe oligoasthenoteratospermia
[severe oligospermia (<5 million sperm/ml), asthenospermia
(<5 % progressive motility), or teratospermia (<4 % normal
forms by strict criteria)] according to WHO criteria [21], ix)
only coupleswith sperm can be obtained from ejaculation, sowe
totally excluded couples who had surgical sperm extraction or
aspiration indication due to azoospermia. Patients gave their
written informed consent and did not receive any monetary
compensation for participating in the study. Only the first cycle
of each patient was included in the study.
All women received the long gonadotropin-releasing hor-
mone agonist protocol for controlled ovarian hyper stimula-
tion (COH). To achieve pituitary desensitization, leuprolide
acetate (Lucrin®; Abbott Laboratories, Istanbul, Turkey) was
initiated on day 21 of the previous cycle at a dose of 10 U, and
it was decreased to 5 U on days 2–3 of menstrual bleeding. As
soon as menstruation began, ovarian stimulation was initiated
with 150–250 U/day rec-FSH (Puregon®; MSD, Istanbul,
Turkey). Recombinant hCG (Ovitrelle®, Serono, Istanbul,
Turkey) was applied when ≥3 follicles reached ≥17 mm, and
oocyte pick-up (OPU) was performed under sedation at the
36th hour following hCG. On oocyte retrieval day, sperm was
collected into a sterile plastic container from males who
refrained from ejaculation for 3–5 days prior to the procedure.
Following sperm preparation with a density gradient method,
the ICSI procedure was performed using sperm that was
selected by embryologists 2–3 h after OPU. A fertilization
(two pronuclei) check was performed on embryos that were
followed in cleavage stage medium (G1.3; Vitrolife®,
Kungsbacka, Sweden) at 16–18 h, and embryos were ob-
served until the 3rd day after OPU. After embryologists
performed a control on the 3rd day, one embryo that was
grade I according to the ESHRE consensus [4] was selected
for transfer. All transfers were performed under ultrasonogra-
phy, and a soft transfer catheter was used (Wallace Embryo
Replacement Catheter, Ref. 1816N; Smiths Medical
International Limited, Kent, UK).
Serum hCG levels were measured in all patients on the
14th day following ET. Patients with >50 IU/L hCG level
were evaluated as pregnancy positive. In patients with a
positive initial hCG measurement, a twofold increase was
evaluated after 48 h. Transvaginal ultrasonography was
performed 3 weeks later in patients who showed an increase,
and those with a fetal structure and fetal cardiac activity
were considered as clinical pregnancy positive.
Prior to and after oocyte retrieval and prior to and after
transfer, 3–5 ml of fasting blood sample was collected from
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the forearm between 8 and 10 am in all women and
centrifuged at 3,000 rpm, and attained sera were kept at
−80 °C. The total oxidant status (TOS) in the plasma was
measured using a novel automated colorimetric measure-
ment method developed by Erel. According to this method,
oxidants present in the sample oxidize the ferrousion-o-
dianisidine complex to ferric ion. The results are expressed
in terms of micromole hydrogen peroxide equivalent per
liter (μmol H2O2 Eq/L) [10]. The total antioxidant status
(TAS) in the plasma was measured using a novel automated
colorimetric measurement method developed by Erel [9].
According to this method, the hydroxyl radical, which is
produced by the Fenton reaction, reacts with the colorless
substrate o-dianisidine to produce the bright yellowish-
brown dianisyl radical. The assay results are expressed as
mmol Trolox Eq/L. TAS and TOS levels in 4 phases of
treatment cycle (before OPU, after OPU, before ET, after
ET) between clinically pregnant and clinically non-pregnant
patients were compared. Critical cut-off values of signifi-
cantly different TAS and TOS levels for clinical pregnancy
were calculated. The oxidative stress indexes (OSI:
TOS/TAS) for the evaluation of systemic oxidative stress
and antioxidant response in ovarian stimulation and
intracytoplasmic sperm injection (ICSI) outcomes were also
calculated and critical cut-off value for significant OSIes
were found.
This study was statistically analyzed using SPSS IBM 20
and Medcalc 11.3. For all variables, the Shapiro Wilk test
was used to assess normality. For normally distributed vari-
ables, paired-sample t-tests and independent-sample t-tests
were applied, and the mean ± standard deviation values
were presented. Wilcoxon’s signed rank test and the
Mann–Whitney U test were applied for non-normally dis-
tributed variables, and median (25 %–75 %) percentiles
were presented. Critical cut-off values of significantly dif-
ferent TAS and TOS levels, OSIes for clinical pregnancy
Table 1 The demographic
characteristics of the study
population
Data are represented with the
form of the Mean ± Standard
Deviation (SD)
BMI Body Mass Index; FSH
Follicle Stimulating Hormone;
LH Luteinizing Hormone; NS
Non-significant







Female age (years) 31.5±3.9 32±3.2 NS
BMI (kg/m2) 23.4±2.9 24.2±2.1 NS
Duration of infertility (years) 3.1±1.9 2.9±2.0 NS
Basal FSH (mIU/ml) 7.1±2.1 8.3±1.6 NS
Basal LH (mIU/ml) 5.1±1.2 4.7±1.4 NS
Basal estradiol (pg/ml) 37±7 36±9 NS
Basal antral follicle count 9±2.1 10±1.9 NS
Number of retrieved oocytes 15±4.1 14±4.9 NS
Fertilization rate (%) 85±6.1 79±4.9 NS
Number of day-3 grade I+II embryos 7±2.3 6±3.0 NS
Number of transferred embryos 1±0 1±0 NS
Table 2 TAS and TOS levels before-after oocyte collection, before-after embryo transfer in clinically pregnant and non-pregnant women
Clinically pregnant (n=22) Clinically non-pregnant (n=48) P value
TAS before OPU 1,70(1,55–1,70) 1,55(1,54–1,59) 0.035
TAS after OPU 1,66(1,58–1,68) 1,58(1,57–1,62) 0,010
TOS before OPU 1,66(1,58–1,68) 1,60(1,54–1,62) 0.092
TOS after OPU 1,63±,057 1,58±,050 0,013
TAS before ET 1,65±,072 1,59±,054 0,022
TAS after ET 1,68±,059 1,62±,052 0.010
TOS before ET 1,65±,063 1,58±,062 0.014
TOS after ET 1,62±,061 1,57±,066 0.065
For normally distributed variables Mean ± Standard Deviation (SD) values were given, for non-normally distributed variables median (25 %–75 %)
percentiles were given
Serum total anti-oxidant (TAS) in mmol Trolox Eq/L unit and serum total oxidant (TOS) in μmol H2O2 Eq/L unit
OPU oocyte pick-up, ET embryo transfer
P-value <0.05 was considered statistically significant
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were evaluated with ROC curve analysis. According to
power analysis calculations, the power of the study was
>80 % for measurements of TAS before and after ET and
TOS after oocyte retrieval. The sample size must be at least
14 in each group to obtain 80 % power for TOS measure-
ments before ET and at least 24 for TOS measurements after
ET. A power analysis was performed for variables that were
evaluated with parametric statistical tests.
Results
The cycle outcome and clinical data of 70 couples with
primary infertility are summarized in Table 1. No significant
difference was noted between couples who had positive
clinical pregnancy and those who did not in terms of the
woman’s age, duration of infertility, day 3 FSH-LH-
estradiol levels, day 3 AFC, number of retrieved oocytes,
number of day 3 grade I+II embryos or number of trans-
ferred embryos.
Measurements obtained prior to OPU in patients with
and without clinical pregnancy revealed median TOS
levels of 1.66 μmol H2O2 Eq/L and 1.60 μmol H2O2
Eq/L (P=0.092), respectively, and median TAS levels of
1.70 mmol Trolox Eq/L and 1.55 mmol Trolox Eq/L
(P=0.035), respectively. Measurements obtained after
OPU in patients with and without clinical pregnancy
revealed mean TOS levels of 1.63 μmol H2O2 Eq/L and
1.58 μmol H2O2 Eq/L (P=0.013), respectively, and medi-
an TAS levels of 1.66 mmol Trolox Eq/L and 1.58 mmol
Trolox Eq/L (P=0.010), respectively (Table 2).
Prior to ET in patients with and without clinical pregnancy,
the mean TOS levels were 1.65 μmol H2O2 Eq/L and
1.58 μmol H2O2 Eq/L (P=0.014), respectively, and the mean
TAS levels were 1.65 mmol Trolox Eq/L and 1.59 mmol
Trolox Eq/L (P=0.022), respectively. Measurements obtained
after ET in patients with and without clinical pregnancy re-
vealed mean TOS levels of 1.62 μmol H2O2 Eq/L and
1.57 μmol H2O2 Eq/L (P=0.065), respectively, and mean
TAS levels of 1.68 mmol Trolox Eq/L and 1.62 mmol
Trolox Eq/L (P=0.010), respectively (Table 2). The TAS
levels in patients with clinical pregnancy were significantly
higher prior to and after OPU and ET (Fig. 1, Table 2). In
addition, TOS measurements after OPU and prior to ETwere
significantly higher in patients who had clinical pregnancy
(Table 2). Comparison of TOS and TAS levels in different
phases of COH cycles in clinically pregnant and non-pregnant
patients were demonstrated in Tables 3 and 4.
According to OSI calculations it was found that; only the
pre-OPU OSI was significantly lower in clinically pregnant
patients (0.970) compared with non-pregnant ones (1.006)
(P=0.008) (Table 5). Critical cut-off values of significantly
different TAS and TOS levels, OSIes for clinical pregnancy
were determined. They were <0.98 mmol Trolox Eq/μmol
H2O2 Eq with AUC = 0.806 (95%CI, 0.617–0.928) and
p=0.001 for OSI before OPU; >1.6 mmol Trolox Eq/L with
AUC = 0.747 (95%CI, 0.552–0.889) and p=0.032 for TAS
before OPU; >1.65 mmol Trolox Eq/L with AUC = 0.800
(95%CI, 0.611–0.924) and p<0.001 for TAS after




































Fig. 1 Serum total antioxidant
status (TAS) levels in clinically
pregnant and non-pregnant
women around oocyte
collection and embryo transfer
Table 3 Comparison of TOS and TAS levels in different phases
during COH cycles in clinically pregnant patients
Phases of cycle
TOS levels P value
Before OPU-after OPU 1,61±,061–1,63±,057 0.014
Before ET-after ET 1,65±,063–1,62±,061 0,003
Before OPU-after ET 1,61±,061–1,62±,061 0.528
TAS levels P value
Before OPU-after OPU 1,64±,075–1,64±,049 0,831
Before ET-after ET 1,68(1,57–1,72)–1,71
(1,63–1,74)
0.007
Before OPU-after ET 1,64±,075–1,68±,059 0.003
For normally distributed variables Mean ± Standard Deviation (SD)
values were given, for non-normally distributed variables median
(25 %–75 %) percentiles were given
Serum total anti-oxidant (TAS) in mmol Trolox Eq/L unit and serum
total oxidant (TOS) in μmol H2O2 Eq/L unit
OPU oocyte pick-up, ET embryo transfer
P-value <0.05 was considered statistically significant
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(95%CI, 0.526–0.871) and p=0.074 for TAS before
ET; >1.67 mmol Trolox Eq/L with AUC = 0.786 (95%CI,
0.595–0.916) and p=0.003 for TAS after ET; >1.64 μmol
H2O2 Eq/L with AUC = 0.758 (95%CI, 0.564–0.897) and
p=0.016 for TOS after OPU; >1.64 μmol H2O2 Eq/L with
AUC = 0.761 (95%CI, 0.567–0.899) and p=0.017 for TOS
before ET. ROC analysis of significantly different seven
measurements were shown in Figs. 2 and 3.
Discussion
Our study showed that the blood TAS level during OPU (pre
and post) and ET (pre and post), most likely the most
important phases in the ART-ICSI cycle, has a predictive
value for clinical pregnancy. All measurements obtained
before and after these important stages showed that TAS
levels were significantly higher in patients who developed
clinical pregnancy; the TAS levels before OPU were
1.70 mmol Trolox Eq/L vs. 1.55 mmol Trolox Eq/L
(P=0.035), respectively, and 1.66 mmol Trolox Eq/L vs.
1.58 mmol Trolox Eq/L after OPU (P=0.010), respectively.
Before ET, the TAS levels were 1.65 mmol Trolox Eq/L vs.
1.59 mmol Trolox Eq/L (P=0.022) in patients with and
without clinical pregnancy, respectively, and after ET, the
TAS levels were 1.68 mmol Trolox Eq/L and 1.62 mmol
Trolox Eq/L (P=0.010), respectively.
Although oxidative stress has an impact on male infertil-
ity, the number of studies on female infertility has increased
recently [2, 3]. In an animal model study, Duleba et al. [8]
showed that oxidative stress negatively affected the devel-
opment of theca-interstitial cells. In contrast, oxidants have
been shown to play a role in folliculogenesis, follicular
maturation and ovulation [11, 19, 20]. Thus, it is likely that
oxidative stress may affect oocyte development and the
development of embryos [2]. In a clinical study, Das et al.
[7] found that ROS levels in follicular fluid measured by the
chemiluminescence method have an impact on the develop-
ment and quality of embryos; additionally, the oocyte fertil-
ization capacity diminished as ROS increased in the
follicular fluid of 78 couples who were admitted to IVF
treatment because of tubal infertility.
Oyawoye et al. [14] measured the basal total antioxidant
capacity (TAC) and decline of TAC in the follicular aspirates of
63 couples and 303 follicle aspirations with a ferric-reducing
antioxidant power (FRAP) assay. Although it was interesting to
note that the decline in TAC was lower when the oocytes were
fertilized and higher in association with embryo viability, ROS
may have different effects at different stages of embryo devel-
opment. In our study, in addition to the high levels of TAS at all
measured times in the clinically pregnant group, TOS levels
after OPU and prior to ET were also higher in patients with
clinical pregnancy. But according toOSI values only lower OSI
before OPU was significant for predicting clinical pregnancy.
Moreover the highest AUC value, from the seven different
significant measurements [1) pre-OPU OSI, 2) TAS prior to
OPU, 3) TAS after OPU, 4) TAS before ET, 5) TAS after ET, 6)
TOS after OUP, 7) TOS before ET], was 0.806 and related to
pre-OPU OSI (Figs. 2 and 3). So, high levels of TOS at certain
measurement times support the idea that elevated antioxidant
levels alone are not sufficient for the development of clinical
pregnancy; ROS may affect different phases of embryo
Table 4 Comparison of TOS and TAS levels in different phases
during COH cycles of clinically non-pregnant patients
TOS levels P value
Before OPU-after OPU 1,57±,046–1,58±,050 0.778
Before ET-after ET 1,60(1,54–1,62)–1,58(1,52–1,60) 0,020
Before OPU-after ET 1,57±,046–1,57±,066 0.552
TAS levels P value
Before OPU-after OPU 1,57±,053–1,59±,043 0,017
Before ET-after ET 1,59±,054–1,62±,052 <0.001
Before OPU-after ET 1,57±,053–1,62±,052 <0.001
For normally distributed variables Mean ± Standard Deviation (SD)
values were given, for non-normally distributed variables median
(25 %–75 %) percentiles were given
Serum total anti-oxidant (TAS) in mmol Trolox Eq/L unit and serum
total oxidant (TOS) in μmol H2O2 Eq/L unit
OPU oocyte pick-up, ET embryo transfer
P-value <0.05 was considered statistically significant
Table 5 OSI in different phases during COH cycles in clinically pregnant and non-pregnant women
OSI Clinically pregnant (n=22) Clinically non-pregnant (n=48) P value
Before OPU 0,970(0,976–1,000) 1,006(0,987–1,012) 0.008
After OPU 1,000(0,984–1,008) 0,990(0,976–1,009) 0,555
Before ET 0,994(0,994–1,003) 0,997(0,987–1,006) 0.688
After ET 0,965(0,947–0,971) 0,963(0,950–0,979) 0,832
Median (25 %–75 %) percentiles were given
Differences were evaluated with Mann–Whitney U test
OPU oocyte pick-up, ET embryo transfer, OSI oxidative stress index
P-value <0.05 was considered statistically significant
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development, and the balance between oxidants and antioxi-
dants may be as important as the antioxidant concentration.
In most of the studies on the role of ROS and antioxi-
dants in ART treatment instead of clinical pregnancy, oocyte
retrieval and/or fertilization and/or embryo development
were considered as endpoints. Moreover, although isolated
oxidative stress markers were used to determine ROS levels
in some studies, total TOS measurement was performed in
others [7, 11, 14]. Regarding TAS levels, isolated antioxi-
dants were measured in some studies, while total TAS was
measured in others [7, 14, 18]. Additionally, different
methods were used for the measurements. These factors
make it difficult to comment on how TAS and TOS affect
clinical pregnancies because different substances were mea-
sured from different sites using different methods. In this
study, we performed our measurements using the Erel meth-
od, which can determine the total antioxidant level to deter-
mine the TAS level [9]. We also measured TOS levels with
the Erel method, which detects total oxidant levels instead
of different oxidants [10]. In addition, measurements were
obtained in female serum. To achieve clinical pregnancy,
oocyte retrieval, fertilization and embryo development and
endometrial implantation following ET are crucial. For this
reason, we measured TAS and TOS levels only in the female
serum, assuming that antioxidants and oxidants would be
effective in all of the phases (oocyte development, embryo
development and implantation). A unique facet of this study
is that we determined the effect of serum TAS and TOS
levels on predicting clinical pregnancy, which not only re-
flects folliculogenesis and embryogenesis but also systemic
effects that may influence implantation.
In contrast, Oyawoye et al. [15] showed that the total
antioxidant capacity depends on the etiology of infertility.
The follicular total antioxidant capacity was higher in
Fig. 2 ROC curve analysis for OSI before OPU. Sensitivity and
specificity rates were given for pre-OPU OSI value which was signif-
icant for predicting clinical pregnancy and AUC was 0.806 (95%CI,
0.617–0.928) with p=0.001. Pre-OPU OSI as in mmol Trolox Eq/
μmol H2O2 Eq. (OPU; oocyte pick-up, OSI; oxidative stress index)
Fig. 3 ROC Curve analysis for measured variables that were signifi-
cant for predicting clinical pregnancy. Significant critical cut-off values
of TAS and TOS in different phases of COH cycle were given with
sensitivity and specificity rates; a TAS prior to OPU, b TAS after OPU,
c TAS before ET, d TAS after ET, e TOS after OUP, f TOS before ET.
Serum total anti-oxidant (TAS) in mmol Trolox Eq/L unit and serum
total oxidant (TOS) in μmol H2O2 Eq/L unit. OPU; oocyte pick-up,
ET; embryo transfer
770 J Assist Reprod Genet (2013) 30:765–772
patients with unexplained infertility and tubal factor infertility,
while in patients with polycystic ovaries, an increase in total
antioxidant capacity was related to fertilization incompetence.
As Agarwal et al. [3] noted an imbalance between pro-
oxidants and antioxidants can cause pathologies such as;
endometriosis, PCOS, unexplained infertility and obstetric
complications such as; abortion and preeclampsia. Therefore
to improve the homogeneity of our study population, only
infertile couples with male factor infertility were included in
this study and most probably this is one of the most important
limitations of our study. There is no suspicion about the effect
of OS on male fertility, but our aim was to evaluate the effect
of female OS on obtaining clinical pregnancy which develops
after successful folliculogenesis, fertilization, embryogenesis
and implantation. Studying with only male factor infertility
couples is one of the most suitable designs that could show us
the effect of female OS on clinical pregnancy. Additionally we
also studied couples only with sperm can be obtained from
ejaculation, so we totally excluded couples who had surgical
sperm extraction or aspiration indication due to azoospermia.
New studies including study groups of patient’s exclusively
with only one of the female infertility or male infertility
etiology will improve our knowledge about this topic.
Briefly; in an effort to induce the impact of oxidative stress
induced by infertility etiology on our results minimal, we
studied with couples who had only male factor infertility.
On the other hand, a study that was conducted with
salivary stress biomarkers (cortisol and α-amylase) showed
that stress in the fertile window decreased the probability of
conception [13]. The results of this study suggest that in
couples that have similar infertility etiology, smoking status
and age, high levels of serum TAS levels prior to and after
OPU and ET increase the chance of pregnancy. Therefore,
the amount of stress and the resultant imbalance between
pro-oxidants and antioxidants in women during ART cycles
has an impact on the occurrence of spontaneous pregnancy.
In our study, we did not measure stress biomarkers, but due
to the homogeneity of our study population, we believe that
one of the most probable factors that affected the pregnancy
rates and TAS/TOS levels is stress. Due to stress-related
imbalances in oxidants and antioxidants, clinical pregnancy
development was affected.
Currently, the trend is multivitamin and mineral supple-
mentation in infertile patients in the aim of strengthening the
antioxidant defense mechanism [16]. However, it seems
obvious that we must strike a balance between antioxidants
and oxidants instead of supplying infertile patients with
antioxidant medications. Additionally, we must also attempt
to decrease the stress of infertile patients.
One of the other limitations of the present study is that it is a
prospective cohort study and not a randomized controlled
trial; therefore, there may have been confounding variables
influencing the results. However, we were able to show that
the two study groups were comparable with respect to several
parameters, including age, body mass index, and basal serum
FSH levels, and therefore, the possibility of selection bias
appear minimal. In contrast, none of the tests used for mea-
suring TAS and/or TOS were demonstrated as the gold stan-
dard, and there is no consensus regarding which antioxidants
or oxidants must be measured. However, we used novel Erel
methods for both of the measurements.
In conclusion, in ART treatment cycles entirely indicated
for male factor infertility, women with higher serum TAS
levels in four major phases of COH cycles (pre-OPU, post-
OPU, pre-ET, post-ET) and with higher TOS levels pre-
OPU and post-ET have an increased probability of clinical
pregnancy. Additionally; OSI before OPU was one of the
most important determinants for clinical pregnancy so the
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